(Q44685785)

5 December 2017

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial (English)

1 reference

5 December 2017

0 references

K P Johnson

1

1 reference

5 December 2017

B R Brooks

2

1 reference

5 December 2017

C C Ford

3

1 reference

5 December 2017

A D Goodman

4

1 reference

5 December 2017

R P Lisak

5

1 reference

5 December 2017

L W Myers

6

1 reference

5 December 2017

A A Pruitt

7

1 reference

5 December 2017

M A Rizzo

8

1 reference

5 December 2017

J W Rose

9

1 reference

5 December 2017

L P Weiner

10

1 reference

5 December 2017

J S Wolinsky

11

1 reference

5 December 2017

1 December 2003

1 reference

Multiple Sclerosis Journal

5 December 2017

1 reference

5 December 2017

9

1 reference

5 December 2017

6

1 reference

5 December 2017

585-591

1 reference

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis.

5 December 2017

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS961OA

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS961OA

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS961OA

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS961OA

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS961OA

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS961OA

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS961OA

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS961OA

Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS961OA

10.1191/1352458503MS961OA

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference